Dogwood Therapeutics, Inc.

  • About
    • Corporate Profile
    • Leadership
    • Board of Directors
    • Corporate Presentation
  • Technology
    • NaV 1.7
    • Antiviral Combination
  • Diseases
    • CINP
    • Long Covid
    • Fibromyalgia
  • Pipeline
  • Clinical Trials
    • CINP 203
  • Investors
  • News

Press Releases

Investors

Investors

  • Overview
  • News
    • Press Releases
    • Email Alerts
  • Events & Presentations
    • Events
    • Presentations
    • Shareholder Letters
    • Meeting
  • Governance
    • Overview
    • Leadership
    • Board of Directors
    • Board Committees
    • Governance Documents
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Financial & Stock Info
    • Overview
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • Resources
    • Overview
    • IR Contacts
    • FAQ
    • Email Alerts
  • News

  • Press Releases
  • Email Alerts
Sep 19, 2022 4:05pm EDT

Virios Therapeutics, Inc. Announces Proposed Public Offering

Sep 19, 2022 7:05am EDT

Virios Therapeutics Announces Top-Line Results from Phase 2b Study of IMC-1 in Fibromyalgia

Aug 15, 2022 7:05am EDT

Virios Therapeutics’ Announces Dosing of First Patient in IMC-2 Long-COVID Treatment Trial

Aug 11, 2022 7:05am EDT

Virios Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update

Aug 10, 2022 4:01pm EDT

Virios Therapeutics, Inc. to Present at Investor Summit Group’s Q3 Virtual Conference

Aug 04, 2022 7:05am EDT

Virios Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on Thursday, August 11, 2022

Jun 01, 2022 7:05am EDT

Virios Therapeutics’ Study Featured in Peer-Reviewed Journal Publication Highlighting Association of Herpes Simplex Type 1 Viral Infection with Common Gastrointestinal Disorders, Including in Patients with Comorbid Fibromyalgia

May 12, 2022 7:05am EDT

Virios Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update

May 05, 2022 7:05am EDT

Virios Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on Thursday, May 12, 2022

Apr 28, 2022 7:05am EDT

Virios Therapeutics Completes Enrollment of 425 Patients in Phase 2b “FORTRESS” Clinical Trial for Fibromyalgia

  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
RSS
  • Email Alerts
  • Contacts
  • RSS News Feed

© 2025 Dogwood Therapeutics, Inc.           Terms and Conditions Privacy Policy Social Media Guidelines